• +1-646-491-9876
    • +91-20-67278686

    Search

    Meningioma-Pipeline Review H1 2017

    Meningioma-Pipeline Review H1 2017

    • Report Code ID: RW0001834407
    • Category Pharmaceuticals
    • No. of Pages 71
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Meningioma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Meningioma - Pipeline Review, H1 2017, provides an overview of the Meningioma (Oncology) pipeline landscape.

    A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid and pia mater. Most meningiomas (90%) are categorized as benign tumors, with the remaining 10% being atypical or malignant. There is no obvious cause of a meningioma. However, this type of brain tumor is about three times more common in women than in men. A meningioma can cause symptoms by pressing on the brain or spinal cord.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Meningioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Meningioma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Meningioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Phase 0 stages are 5, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Meningioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Meningioma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Meningioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Meningioma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Meningioma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Meningioma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Meningioma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Meningioma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Meningioma - Overview
    Meningioma - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Meningioma - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Meningioma - Companies Involved in Therapeutics Development
    Arno Therapeutics Inc
    AstraZeneca Plc
    Boehringer Ingelheim GmbH
    GlaxoSmithKline Plc
    Novartis AG
    Pharma Mar SA
    Progenics Pharmaceuticals Inc
    Meningioma - Drug Profiles
    afatinib dimaleate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AR-42 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Edotreotide Labeled Yttrium 90 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2256098 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HXR-9 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pasireotide ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    selumetinib sulfate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    trabectedin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    vistusertib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Meningioma - Dormant Projects
    Meningioma - Discontinued Products
    Meningioma - Product Development Milestones
    Featured News & Press Releases
    Sep 21, 2015: Enrollment of first patient in a Phase II trabectedin study in brain tumor type called meningioma
    Jun 07, 2012: Arno Therapeutics Announces Additional Orphan-Drug Designations For AR-42 In Europe
    Feb 21, 2012: Arno Therapeutics Receives Two Orphan-Drug Designations For AR-42 To Treat Central-Nervous-System Tumors
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Meningioma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Meningioma - Pipeline by Arno Therapeutics Inc, H1 2017
    Meningioma - Pipeline by AstraZeneca Plc, H1 2017
    Meningioma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Meningioma - Pipeline by GlaxoSmithKline Plc, H1 2017
    Meningioma - Pipeline by Novartis AG, H1 2017
    Meningioma - Pipeline by Pharma Mar SA, H1 2017
    Meningioma - Pipeline by Progenics Pharmaceuticals Inc, H1 2017
    Meningioma - Dormant Projects, H1 2017
    Meningioma - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Meningioma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Arno Therapeutics Inc
    AstraZeneca Plc
    Boehringer Ingelheim GmbH
    GlaxoSmithKline Plc
    Novartis AG
    Pharma Mar SA
    Progenics Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//meningioma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//meningioma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//meningioma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments